Acute kidney injury following the use of different proton pump inhibitor regimens: A real‐world analysis of post‐marketing surveillance data

Background and Aim Recent evidence has concerned acute kidney injury (AKI) after the proton pump inhibitor (PPI) application. There are few real‐world studies to compare the occurrences, clinical features, and prognosis of AKI related to various PPI regimens. We aimed to evaluate and compare the lin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2021-01, Vol.36 (1), p.156-162
Main Authors: Chen, Gang, Ning, Li‐Juan, Qin, Yan, Zhao, Bin, Mei, Dan, Li, Xue‐Mei
Format: Article
Language:English
Subjects:
Acute kidney injury
Adverse event reporting system
Adverse events
Bayesian analysis
Confidence intervals
Epidemiology
Fatalities
Kidneys
Omeprazole
Prognosis
Proton pump inhibitor
Proton pump inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Recent evidence has concerned acute kidney injury (AKI) after the proton pump inhibitor (PPI) application. There are few real‐world studies to compare the occurrences, clinical features, and prognosis of AKI related to various PPI regimens. We aimed to evaluate and compare the links between different PPIs and AKI in a large population by investigating the Food and Drug Administration Adverse Event Reporting System (FAERS) until recently. Methods Disproportionality analysis and Bayesian analysis were used in data mining to screen the suspected AKI after different PPIs based on the FAERS from January 2004 to December 2019. The times to onset, fatality, and hospitalization rates of PPI‐associated AKI were also investigated. Results We identified 19 522 PPI‐associated AKIs, which appeared to influence more middle‐aged patients than elderly ones (53.04% vs 33.94%). Women were more affected than men (55.42% vs 44.58%). Lansoprazole appeared a stronger AKI association than other PPIs, based on the highest reporting odds ratio (reporting odds ratio = 20.8, 95% confidence interval = 20.16, 21.46), proportional reporting ratio (proportional reporting ratio = 15.55, χ2 = 73 899.68), and empirical Bayes geometric mean (empirical Bayes geometric mean = 15.15, 95% confidence interval = 14.76). The median time to AKI onset was 446 (interquartile range [IQR] 16–2176) days after PPI administration. PPIs showed a significant difference in average time to AKI onset (P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.15151